ProMIS Neurosciences Inc. (ON) Share Price
NASDAQ: PMN | Micro CapProMIS Neurosciences Inc. (ON) Stock Performance
Open $13.39 | Prev. Close $13.29 | Circuit Range N/A |
Day Range $13.39 - $13.50 | Year Range $0.29 - $27.05 | Volume 404 |
Average Traded $13.45 |
ProMIS Neurosciences Inc. (ON) Share Price Today
As of 9 August 2026, ProMIS Neurosciences Inc. (ON)'s share price is $13.50. The stock opened at $13.39, compared to its previous close of $13.29. During today's trading session, ProMIS Neurosciences Inc. (ON)'s share price traded between $13.39 and $13.50, with an average price of $13.45. Over the past 52 weeks, the stock has recorded a high of $27.05 and a low of $0.29. In terms of performance, ProMIS Neurosciences Inc. (ON)'s share price has declined by 42.68% over the last six months and is up 2413.97% on a year-on-year basis.
ProMIS Neurosciences Inc. (ON) Share Price Chart
ProMIS Neurosciences Inc. (ON) Stock Fundamentals & Key Indicators
Market Cap $23.72M | PE Ratio (TTM) -0.60 | Dividend Yield N/A |
EPS (TTM) $-22.61 | Revenue (TTM) N/A | Return On Equity (TTM) 3155.84% |
Profit Margin N/A | Debt to Equity -8.27 | Quarterly Earnings Growth YoY -224.84% |
ProMIS Neurosciences Inc. (ON) Quarterly Profit & Loss
All figures in USD
ProMIS Neurosciences Inc. (ON) Annual Profit & Loss
All figures in USD
About ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
ProMIS Neurosciences Inc. (ON) Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $14.27 | $13.48 | -2.18% |
Jul 2026 | $13.47 | $13.78 | +2.91% |
Jun 2026 | $10.48 | $13.39 | +20.31% |
May 2026 | $11.01 | $11.13 | +1.09% |
Apr 2026 | $12.96 | $11.01 | -14.72% |
Mar 2026 | $21.21 | $12.91 | -45.18% |
Feb 2026 | $13.41 | $23.55 | +66.43% |
Jan 2026 | $7.04 | $14.15 | +102.43% |
Dec 2025 | $6.75 | $6.99 | +3.63% |
Nov 2025 | $0.41 | $6.75 | +1,513.64% |
Oct 2025 | $0.43 | $0.42 | -0.48% |
Sep 2025 | $0.54 | $0.42 | -21.79% |
PMN Share Price FAQs
What is ProMIS Neurosciences Inc. (ON) share price today?
What is the 52 week high and 52 week low of ProMIS Neurosciences Inc. (ON) stock?
What is PMN's market capitalisation today?
What is PMN's net income for the last quarter?
What is the 5 year returns of PMN?
What is the high & low stock price of PMN today?
Can I buy PMN shares in India?